Persistent Disease Activity Remains a Burden for Patients with Systemic Lupus Erythematosus

被引:12
|
作者
Peschken, Christine A. [1 ,2 ]
Wang, Yishu [3 ]
Abrahamowicz, Michal [3 ]
Pope, Janet [4 ,5 ]
Silverman, Earl [6 ,7 ]
Sayani, Amyn [8 ]
Iczkovitz, Sandra [8 ]
Ross, Jorge [9 ]
Zummer, Michel [10 ]
Tucker, Lori [11 ]
Pineau, Christian [12 ]
Levy, Deborah [6 ,7 ]
Hudson, Marie [13 ,14 ]
Hitchon, Carol A. [1 ]
Huber, Adam M. [15 ,16 ]
Smith, C. Douglas [17 ]
Avina-Zubieta, Antonio [18 ]
Arbillaga, Hector [19 ]
Chedeville, Gaelle [20 ]
Wynant, Willy [3 ]
Fortin, Paul R. [21 ]
机构
[1] Univ Manitoba, Dept Internal Med, Winnipeg, MB, Canada
[2] Univ Manitoba, Dept Community Hlth, Winnipeg, MB, Canada
[3] McGill Univ, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ, Canada
[4] Univ Western Ontario, London, ON, Canada
[5] St Josephs Hlth Care London, London, ON, Canada
[6] Hosp Sick Children, Toronto, ON, Canada
[7] Univ Toronto, Toronto, ON, Canada
[8] GlaxoSmithKline Inc, Med Affairs, Mississauga, ON, Canada
[9] GlaxoSmithKline Inc, King Of Prussia, PA USA
[10] Maisonneuve Rosemont, Montreal, PQ, Canada
[11] BC Childrens Hosp, Vancouver, BC, Canada
[12] McGill Univ, Hlth Ctr, Montreal, PQ, Canada
[13] Jewish Gen Hosp, Lady Davis Inst, Montreal, PQ, Canada
[14] McGill Univ, Montreal, PQ, Canada
[15] IWK Hlth Ctr, Halifax, NS, Canada
[16] Dalhousie Univ, Halifax, NS, Canada
[17] Univ Ottawa, Ottawa, ON, Canada
[18] Univ British Columbia, Div Rheumatol, Arthrit Res Canada, Vancouver, BC, Canada
[19] Rheumatol Clin, Calgary, AB, Canada
[20] McGill Univ, Hlth Ctr, Montreal Childrens Hosp, Montreal, PQ, Canada
[21] Univ Laval, CHU Quebec, Dept Med, Div Rheumatol, Laval, PQ, Canada
关键词
SYSTEMIC LUPUS ERYTHEMATOSUS; DISEASE ACTIVITY; 1000 CANADIAN FACES; DOUBLE-BLIND; SOCIOECONOMIC-STATUS; ORGAN DAMAGE; ACTIVITY INDEX; ACTIVITY STATE; EFFICACY; SAFETY; COHORT; HEALTH;
D O I
10.3899/jrheum.171454
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. Persistent systemic lupus erythematosus (SLE) disease activity is associated with increased morbidity and mortality. In a multicenter cohort of patients with prevalent SLE, we described persistence, patterns, and predictors of change in disease activity over time. Methods. Based on SLE Disease Activity Index (SLEDAI)-2K scores at cohort entry, patients were classified into 4 groups: low (score < 4; LOW), moderate (4 to < 6; MOD), moderately high (6 to <= 10; MHIGH), and very high (> 10; VHIGH). Multivariable linear and longitudinal mixed linear regression models were used to identify predictors of change over time in SLEDAI-2K. Results. There were 2019 participants, with declining followup data over 5 years (1326, 580, 274, 186, and 148 patients, respectively). At cohort entry, mean (+/- SD) age was 42 (+/- 17) years, disease duration 11 (+/- 10) years, and 90% were female. The 4 groups included 44% LOW (n = 891), 20% MOD (n = 400), 22% MHIGH (n = 442), and 14% VHIGH (n = 286); therefore, 36% had clinically important SLE activity. The proportion of patients in the LOW group at entry who moved to a higher activity level varied from 30% (167/557) at 1 year, to 49% (41/83) at 3 years, and 54% (30/56) at 5 years. Among 181 patients with MOD to VHIGH entry activity and 3 years of followup, 116 (64.1%) remained active. In all analyses, only higher SLEDAI-2K at cohort entry remained a significant predictor of higher SLEDAI-2K in subsequent years. Conclusion. Higher SLEDAI-2K at study entry was the single major independent predictor of higher SLEDAI-2K over time, reflecting frequent persistence of active disease, even in patients with longstanding disease. This highlights gaps in the optimal treatment of SLE.
引用
收藏
页码:166 / 175
页数:10
相关论文
共 50 条
  • [1] Peripheral immunophenotypes associated with the flare in the systemic lupus erythematosus patients with low disease activity state
    Zheng, Jian
    Zhu, Li
    Ju, Bomiao
    Zhang, Jing
    Luo, Jing
    Wang, Yanhua
    Lv, XiaoHong
    Pu, Dan
    He, Lan
    Wang, Jing
    CLINICAL IMMUNOLOGY, 2022, 245
  • [2] Improving measures of disease activity in systemic lupus erythematosus
    Banjari, Maher
    Touma, Zahi
    Gladman, Dafna D.
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2023, 19 (02) : 193 - 202
  • [3] Tuberculosis remains a major burden in systemic lupus erythematosus patients in Durban, South Africa
    Al-arbi, Khaled Mohamed Sefow
    Magula, Nombulelo P.
    Mody, Girish M.
    FRONTIERS IN MEDICINE, 2023, 10
  • [4] Association of calreticulin expression with disease activity and organ damage in systemic lupus erythematosus patients
    Wang, Yichao
    Xie, Jiaogui
    Liu, Zhili
    Fu, Hongwei
    Huo, Qianyu
    Gu, Yajun
    Liu, Yunde
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2017, 13 (05) : 2577 - 2583
  • [5] Association of the Spectrum of Cutaneous Lupus Erythematosus with Disease Activity and Systemic Manifestations in Patients with Systemic Lupus Erythematosus
    Brahmanti, Herwinda
    Wahono, Cesarius Singgih
    Pratama, Mirza Zaka
    Rahman, Perdana Aditya
    Suhendra, Riski Bagus
    Rizky, Amalia Novia
    Mukti, Nabilah Hanifah
    MEDITERRANEAN JOURNAL OF RHEUMATOLOGY, 2024, 35 (01): : 143 - 149
  • [6] Analysis of disease activity and response to treatment in a large Spanish cohort of patients with systemic lupus erythematosus
    Pego-Reigosa, J. M.
    Rua-Figueroa, I.
    Lopez-Longo, F. J.
    Galindo-Izquierdo, M.
    Calvo-Alen, J.
    Olive-Marques, A.
    del Campo, V.
    Garcia-Yebenes, M. J.
    Loza-Santamaria, E.
    Blanco, R.
    Melero-Gonzalez, R.
    Vela-Casasempere, P.
    Oton-Sanchez, T.
    Tomero-Muriel, E.
    Uriarte-Isacelaya, E.
    Fito-Manteca, M. C.
    Freire-Gonzalez, M.
    Narvaez, J.
    Fernandez-Nebro, A.
    Zea-Mendoza, A.
    Carlos Rosas, J.
    LUPUS, 2015, 24 (07) : 720 - 729
  • [7] Predicting the effect of sirolimus on disease activity in patients with systemic lupus erythematosus using machine learning
    Wang, Dong-Dong
    Li, Ya-Feng
    Zhang, Cun
    He, Su-Mei
    Chen, Xiao
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2022, 47 (11) : 1845 - 1850
  • [8] Defining Low Disease Activity in Systemic Lupus Erythematosus
    Polachek, Ari
    Gladman, Dafna D.
    Su, Jiandong
    Urowitz, Murray B.
    ARTHRITIS CARE & RESEARCH, 2017, 69 (07) : 997 - 1003
  • [9] Modelling long-term outcomes for patients with systemic lupus erythematosus
    Touma, Z.
    Kayaniyil, S.
    Parackal, A.
    Bonilla, D.
    Su, J.
    Johnston, A.
    Gahn, J.
    Hille, E. D.
    Ohsfeldt, R.
    Chandran, S.
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2024, 68
  • [10] Ovarian function and disease activity in patients with systemic lupus erythematosus
    Shabanova, S. S.
    Ananieva, L. P.
    Alekberova, Z. S.
    Guzov, I. I.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2008, 26 (03) : 436 - 441